Vivalytic | MG, MH, UP/UU Rapid Test

Home - vivalytic - Page 3

Vivalytic | MG, MH, UP/UU Rapid Test

Vivalytic | MG, MH, UP/UU Rapid Test

 

Detection of Mycoplasma genitalium, Mycoplasma hominis & Ureaplasma parvum/urealyticum

RT-PCR detection of common STI pathogenic bacterial species

  • null
    Quick turnaround time of 53 minutes, beneficial for both the patient and for the containment of STIs
  • null
    Convenient 4 step process from sample entry to results. Suitable for use in laboratory and non-laboratory settings
  • null
    Detection from a wide range of sample types including urine, urethral, vaginal, cervical and rectal swabs

Clinical Significance

Aiding in the diagnosis and containment of sexually transmitted infections (STIs) of symptomatic and asymptomatic individuals, the Vivalytic portfolio of tests has now expanded to complement current comprehensive screening.

The Mycoplasma genitalium (MG), Mycoplasma hominis (MH) & Ureaplasma parvum (UP)/urealyticum (UU) test guides appropriate treatment decisions at the earliest opportunity for improved patient management, prevention of transmission and supporting emerging macrolide resistance. MG, MH, UP/UU belong to the group of human pathogenic bacterial species associated with STIs even though particularly Ureaplasma ssp. are primarily considered as commensal organisms.

All four bacterial species can be detected simultaneously with the Vivalytic MG, MH, UP/UU test cartridge. 

* Detailed information on the determination of analytical performance can be found in instructions for use provided with the testing kit.

 

Features

Sample Type: Swab (Urethral, Vaginal, Cervical, Rectal), Urine

Sample Volume: 300 μl

Detection Method: Real-Time PCR

Time to result: 53 minutes

 

Detectable Bacteria
Mycoplasma genitalium
Mycoplasma hominis
Ureaplasma parvum/urealyticum

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Vivalytic | MRSA & MSSA Rapid Test

Vivalytic | MRSA/MSSA Rapid Test

Rapid differentiation between MRSA & MSSA in 53 minutes

Bacterial Differentiation to Promote Targeted Therapy

  • null
    Improves patient pathways and the need for care with screening at both ward level, emergency settings and before elective surgery procedures identifying suspected sensitive or resistant bacterial staphylococcus strains.
  • Early Error Detection
    Speed is key – 53 minutes for results vs 1-3 days for culture sampling
  • null
    MRSA/SA screening contributes to current health risks by preventing contamination, breaking the chain of infection, and fighting against antimicrobial resistance and superbugs.

Clinical Significance

MRSA/SA is a qualitative RT-PCR test detecting and differentiating between methicillin-resistant Staphylococcus aureus (MRSA), methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). By using one single cartridge, the Vivalytic MRSA/SA test aids in the diagnosis of MRSA infection in a speedy manner so that appropriate antibiotic treatment can be applied, and complications prevented.

 

Vivalytic VS Traditional Culture Methods

The Vivalytic point of care device can provide fast and accurate results, crucial when it comes to treating infectious diseases like MRSA.

Additionally, with closed-system testing  the Vivalytic also offers reduced risk of contamination compared to traditional culture methods. This is because it uses closed-system testing, which minimises the chances of contamination and helps ensure the accuracy of the results.

Moreover, the Vivalytic system also offers reduced time to diagnosis at 53 minutes, which is vital for effective infection control and patient care in comparison to traditional methods which can take up to 2-3 days. With faster and more accurate results, healthcare professionals can quickly isolate and treat patients with MRSA, reducing the risk of spread and improving patient outcomes.

Click image to enlarge

 

Features

Sample Type: Swab

Sample Volume: 600 μl

Detection Method: Real-Time PCR

Time to result: 53 minutes

Detectable Pathogens Specific Gene Targets
Methicillin-resistant Staphylococcus aureus (MRSA) SCCmec/orfX junction, mecA/ mecC, SA422
Methicillin-sensitive Staphylococcus aureus (MSSA)

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

 

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Vivalytic | SARS-CoV-2 Rapid Dual Target

Vivalytic | SARS-CoV-2 Dual Target Rapid Test

Detecting E & N gene sequence for SARS-CoV-2

SARS-CoV-2 Dual Target Detection

  • null
    Detection from real-time PCR via Nasopharyngeal and/Oropharyngeal swab or lollipop swab collection
  • null
    The SARS-CoV-2 rapid test targets the E gene & N gene sequence for COVID-19 detection
  • null
    The SARS-CoV-2 rapid test has recently received CE marking
  • null
    Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround time of just 53 minutes from sample entry to result
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

Clinical Significance

SARS-CoV-2 dual target is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay.

The SARS-CoV-2 dual target rapid test allows for detection of both the E-gene and N-gene sequence for SARS-CoV-2 with minimal workflow required, suitable for laboratory and non-laboratory settings. The SARS-CoV-2 dual target test also contains a Human and Internal PCR control for convenience.

In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first!*

* Detailed information on the determination of analytical performance can be found in instructions for use provided with SARS-CoV-2 kit.

* Test Termination: If one of the target genes is clearly detected, the test can be terminated prematurely with the valid positive result.

 

Features

Sample Type: Nasopharyngeal or Oropharyngeal Swab (eNAT)

Sample Volume: 300 μl

Detection Method: Real-Time PCR

Time to result: 53 minutes

Detectable Virus
SARS-CoV-2 (E-gene and N-gene sequence)

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Pooling Test

Vivalytic

Vivalytic Test Menu


Rapid PCR MRSA/SA testing now available on Vivalytic

https://www.linkedin.com/company/107191

Rapid PCR MRSA/SA testing now available on Vivalytic

Providing a quick diagnosis of methicillin resistant at the point of the care, the latest addition to the Vivalytic portfolio of tests, not only provides rapid RT-PCR results in 53 minutes but differentiates whether the bacterial strain is methicillin-resistant (MRSA) or methicillin-sensitive (MSAA) which promotes targeted therapy.

MRSA is a major multi-resistant nosocomial pathogen worldwide with the WHO estimating that the mortality rate of patient infection rates is around 50% higher compared with patients who have been infected by non-resistant Staphylococcus aureus strains.1 Moreover, the extensive period of hospitalisation, morbidity, and the associated medical costs increase significantly with an MRSA infection.2

Introducing MRSA to the vivalytic portfolio can provide high quality answers, anywhere and anytime improving patient pathways and the need for care. Significantly, introducing rapid MRSA screening at both ward level, emergency settings and before hospital elective surgery procedures allow for an effective response to identifying whether the bacteria strain is methicillin-sensitive (MSSA) or -resistant.

Making a point to care, the rapid essence and speed of Vivalytic not only showcase technology but the ability to contribute to current health risks by preventing contamination, breaking the chain of infection, and again fighting the silent pandemic of antimicrobial resistance (AMR) & superbugs.

The treatment on the front line today looks at increasing empirical antibiotic prescribing and increasing drug-resistant outbreaks. AMR is growing rapidly, with superbugs threatening the ability to treat common infectious diseases appropriately. The COVID-19 pandemic has elevated concerns over AMR and antibiotic-associated adverse events, with surges in antibiotic prescribing, hospitalisations, and drug-resistant bacterial transmissions.

Speed is key here – since the result of diagnostics with culture sampling, which is the current traditional method for MRSA testing is only available after one to three days, this PCR test for the point of care is ideal as an additional tool when speed is of the essence.

 

Few points to note about the current Vivalytic panel for MRSA/SA detection:

  • By using one single cartridge, the Vivalytic MRSA/SA test detects and differentiates between MRSA and MSSA DNA to aid in the diagnosis of MRSA infection in a speedy manner so that appropriate antibiotic treatment can be applied, and complications prevented.
  • Detection Method: Real-Time PCR
  • Result Time: 53 minutes
  • Sample Volume: 600 μl
  • Sample Type: Nasal- or oropharyngeal swab sample

 

DETECTABLE DNA PATHOGENS:SPECIFIC GENE TARGETS:
Methicillin-resistant Staphylococcus aureus (MRSA)SCCmec/orfX junction
Methicillin-sensitive Staphylococcus aureus (MSSA) mecA/ mecC, SA422

Making this happen, The MRSA/SA rapid test on Vivalytic by Bosch, a point of care platform brought to the market by Randox Laboratories. The Vivalytic system is a fully automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex infectious disease testing. Each easy-to-use cartridge contains all necessary reagents, is fully-sealed to minimise risk and can be conveniently stored at room temperature.

The Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection.  It follows an easy 4 step process from sample entry to results and with the gold standard PCR testing. With most up to date technology, the Vivalytic has wireless connectivity, with no peripherals required, making a unique space saving and hygienic solution. Handling and utilisation are simple and medical professionals require only minimal training.

For more information on the Vivalytic, why not visit our webpage- https://www.randox.com/vivalytic-molecular-point-of-care/

For more information on our new MRSA test, please contact market@randox.com

 

ABOUT RANDOX

NEWS

VACANCIES

OUR PEOPLE


National STIQ Day 2022

COVID-19 Testing        News        Contact Us

National STIQ Day 2022

14th January, National STIQ day was launched to get people thinking about the importance of sexual health and encourage everyone to get regular health checks.

More than 30 different bacteria, viruses and parasites are known to be transmitted through sexual contact. Eight of these pathogens are linked to the greatest incidence of sexually transmitted diseases (STI’s). STI’s are spread predominantly by sexual contact, including vaginal, anal and oral sex. Some STI’s can also be transmitted from mother-to-child during pregnancy, childbirth, and breastfeeding.

Any individual can catch an STI regardless of what age they are, their sexuality or how many sexual partners they have, as it only takes one sexual encounter to increase the risk of catching an infection. The importance of regular STI testing allows individuals to get peace of mind and take control of their sexual health as many infections don’t present symptoms and it’s advised that testing is required if individuals are concerned about their health, present symptoms or change sexual partner. Regular screening can aid in detecting an infection in the early stages and help to reduce the risk of such complications.

The increase in STI’s underline the need for urgent action which many reports have highlighted the need of ongoing inaction and development of strategies to improve sexual health. It has been widely noted by the CDC that over 20 million new STI’s are detected each year. (1) Public Health England also reported that 468,342 diagnoses of STIs had been reported in England in 2019 – a 5% increase from 2018 with a 26% increase in gonorrhoea infections, 10% increase in syphilis and 7% increase in the number of consultations at national sexual health services. It’s also widely noted that chlamydia testing, which is most common in young adults has declined by 13% since 2015 and 2% of all individuals tested had received a positive diagnosis. (2) (3)

Here at Randox, we offer solutions for clinical laboratories, point of care testing solutions and home STI testing kits for convenience and discretion. Randox provides the broadest STI testing menu on the market. Detecting 10 bacterial, viral, and protozoan infections, the STI test provides a comprehensive sexual health profile. The CE-marked STI Array provides the identification of co-infections, often in asymptomatic individuals and enable antibiotic stewardship.

The Randox test presents excellent precision, specificity, sensitivity and accuracy for STI diagnoses, which reduces the risk of false reporting and unnecessary confirmatory tests. The Randox simultaneous multiplex test means smaller sample volumes are required, enabling faster throughput and rapid patient diagnosis saving time and money for clinical and laboratories.

The Randox STI Multiplex test detects the following infections:

  • Chlamydia trachomatis (CT)
  • Neisseria gonorrhoeae (NG)
  • Trichomonas vaginalis (TV)
  • Mycoplasma genitalium (MG)
  • Treponema pallidum (Syphilis) (TP)
  • Herpes simplex virus 1 (HSV-1)
  • Herpes simplex virus 2 (HSV-2)
  • Haemophilus ducreyi (HD)
  • Mycoplasma hominis (MH)
  • Ureaplasma urealyticum (UU)

 

Does your laboratory or clinic carry out STI testing? Our molecular analyser, the Bosch Vivalytic and Evidence Investigator, powered by patented Biochip Array Technology, could be the diagnostic solution you need!

Solutions for the Laboratory

54 SAMPLES ● 1 TEST ● 10 INFECTIONS

 The Evidence Investigator is a compact semi-automated benchtop analyser ideal for medium throughput laboratories.

  • Sample Type: Swab or Urine
  • Sample Volume: 300 μl
  • Detection Method: Randox Biochip Technology (end-point PCR)
  • Time to Result: 5 hours 30 minutes

 

STI Testing at the Point of Care

1 SAMPLE ● 1 TEST ● 10 INFECTIONS

The Bosch Vivalytic enables sample to answer, cartridge based molecular diagnostics at

the point of care. Powered by Randox Biochip Technology.

  • Sample Type: Swab or Urine
  • Sample Volume: 300 μl
  • Detection Method: Randox Biochip Technology (end-point PCR)
  • Time to Result: 2 hours 30 minutes

 

For more information about our STI Arrays or Vivalytic email: marketing@randox.com

  1. https://www.cdc.gov/std/life-stages-populations/adolescents-youngadults.htm
  2. https://www.tht.org.uk/news/rise-stis-underlines-need-urgent-action
  3. Sexually transmitted infections (STIs) (who.int)

Related Products and Services

Evidence Investigator

Biosciences

ANTIBODY TEST

Vivalytic


Vivalytic | Extensive SARS-CoV-2 Pooling

Vivalytic | Extensive SARS-CoV-2 Pooling Test

15 Samples, 1 Cartridge 

Simultaneous SARS-CoV-2 detection from up to 15 pooled samples

  • null
    Detection from real-time PCR using saliva lollipop swab collection.
  • null
    Up to 15 patient samples may be pooled and added to a single cartridge targeting the E gene sequence

     

  • null
    The SARS-CoV-2 pooling test has recently received CE marking.
  • null
    Simple and easy to use POC analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround time of less than 45 minutes for results.
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

Extensive SARS-CoV-2 Pooling is a rapid real-time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care on the Vivalytic. The SARS-CoV-2 pooling test with lollipop swab allows for the screening of up to 15 patient samples. One of the first rapid pooling PCR tests on the market, the Vivalytic produces results in less than 45 minutes delivering high accuracy for extensive and faster testing ideal for rapid and confirmatory SARS-CoV-2 screening in any environment.

Ideal for mass testing, the pooling could be done at the level of a ward, medical speciality, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools and universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.

SARS CoV 2 Pooling

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Rapid Test

Vivalytic

Vivalytic Test Menu


SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper

Randox Logo

30 June 2021

SARS-CoV-2 Vascular & Multi-System Dysfunction Whitepaper Download

COVID-19, the disease caused by SARS-CoV-2, is an infectious disease caused by a newly discovered coronavirus. While many of whom become infected by the disease will experience mild to moderate cold or flu-like symptoms, those with health complications – such as autoimmune diseases, asthma, heart disease and diabetes – are at risk of developing serious illness and adverse outcomes.

As of September 2021, over 228 million COVID-19 cases have been confirmed worldwide, with an estimated one in six patients experiencing complications which could be life threatening, with over £116 billion spent by the UK government alone on measures to combat the disease. This drastic spending has been mirrored across the globe, with the significant economic burden expected to be suffered for generations to come.

The whitepaper provides a brief overview of the COVID-19 pandemic, before discussing vascular abnormalities and associated complications brought on by the virus, such as multi-system disfunction, acute respiratory disease syndrome (ARDS) and hepatic, renal & cardiovascular function.

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our COVID-19 Products and Services

HOME TEST

ANTIBODY TEST

TRAVEL CERTIFICATE

LABORATORY TOOLS


Vivalytic | Customer Support

Vivalytic | Customer Support

Molecular Diagnostics at the Point of Care

Video Tutorials

For your support, we have compiled a series of informative video tutorials on how to install and operate the Vivalytic machine. You can use these guides to refresh your knowledge from prior training or to learn about specific procedures step by step.

Installation and Operational Guide

Instructional Promo Video

COVID-19 Testing Process

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Vivalytic Overview

SARS-CoV-2 Rapid Test

SARS-CoV-2 Pooling Test

Vivalytic Test Menu


Vivalytic | SARS-CoV-2 Pooling Test

Vivalytic | SARS-CoV-2 Pooling Test

Detecting SARS-CoV-2 (COVID-19)

Detecting SARS-CoV-2 (COVID-19) from up to 5 Pooled Samples Simultaneously

  • null
    Detection from real-time PCR via Nasopharyngeal and/or Oropharyngeal swab
  • null
    Up to 5 patient samples may be pooled and added to a single cartridge targeting the E gene sequence
  • null
    The SARS-CoV-2 pooling test has recently received CE marking
  • null
    Simple and easy to use POC analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround from sample entry to result, capable of testing up to 160 samples a day
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

Clinical Significance

SARS-CoV-2 Pooling (COVID-19) is a rapid real time PCR test cartridge, providing clear and concise results in a timely manner, direct at the point of care. This enables the patient to take the recommended safety precautions without delay. The pooling could be done at the level of a ward, medical speciality, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools and universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.

In collaboration with Bosch, we are proud to release not only a rapid testing solution for the detection of SARS-CoV-2 (COVID-19) but an accelerated mass testing solution to effectively and efficiently monitor and detect viral infection from the offset with an aim of minimising the rise in infections globally. The new SARS-CoV-2 pooling test will allow users to test up to 160 samples a day and has sensitivity of 98% and a specificity of 100% – a world’s first!* Highly sensitive assays allow for laboratories to accurately detect low positive samples, enabling for effective identification of positive COVID-19 cases in a timely manner.

* Detailed information on the determination of analytical performance can be found in instructions for use provided with SARS-CoV-2 pooling kit.

 

Features

Sample Type: Nasopharyngeal or Oropharyngeal Swab

Sample Volume: 150 μL per-patient sample (If
less than 5 patient samples, supplement the remaining
volume with eNAT solution)

Detection Method: Real-Time PCR

Time to result: 44 minutes

Detectable Pathogens
SARS-CoV-2 (E gene sequence)

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

SARS-CoV-2 Rapid Test

Vivalytic

Vivalytic Test Menu


Vivalytic | Sexually Transmitted Infection Array

Vivalytic | Sexually Transmitted Infection Array

1 Sample | 1 Test | 10 Infections

Comprehensive Sexual Health Profile

  • null
    Detecting 10 bacterial, viral and protozoan infections
  • null
    Sample to answer, cartridge based molecular diagnostics at the point of care. Powered by Randox Biochip Technology
  • null
    The STI array has recently received CE marking
  • null
    Simple and easy to use analyser with a small footprint making it suitable for use in laboratory and non-laboratory settings
  • null
    Rapid turnaround time of just 2 hours 20 minutes from sample entry to result
  • null
    Convenient 4 step process from sample entry to results. No laboratory training required

Clinical Significance

The Sexually Transmitted Infection (STI) array is the broadest multiplex cartridge-based STI test on the market simultaneously detecting 7 bacterial,  2 viral and 1 protozoan infection for a comprehensive sexual health profile.

Globally, each day over 1 million people are exposed to an STI, many of who will not know they have an infection as many STI’s are asymptomatic whilst some individuals will display similar or overlapping symptoms, therefore co-infections may remain undiagnosed. Designed to offer a complete sexual health profile with an aim of prevention and control, the Vivalytic STI array can be used to diagnose existing infections whilst any identifying co-infections.

To find out more about the global economic burden of STIs and the impact of the COVID-19 pandemic on sexual health, download our most recent whitepaper that presents issues such as AMR, the development of super-gonorrhoea, and the challenges faced in a social and public concept due to the COVID-19 pandemic.

Features

Sample Type: Swab or Urine (eNAT, Roche COBAS medium, or PBS)

Sample Volume: 300 μl

Detection Method: Randox Biochip Technology (end-point PCR)

Time to result: 2 hours 20 minutes

Detectable Infections
Chlamydia trachomatis (CT)Herpes simplex virus 1 (HSV-1)
Neisseria gonorrhoeae (NG)
Herpes simplex virus 2 (HSV-2)
Trichomonas vaginalis (TV)
Haemophilus ducreyi (HD)
Mycoplasma genitalium (MG)
Mycoplasma hominis (MH)
Treponema pallidum (Syphilis) (TP)
Ureaplasma urealyticum (UU)

“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”

Vivalytic Workflow

Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.

To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.

The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.

Download Vivalytic Brochure

Want to know more?

Contact us or visit our COVID-19 Monitoring & Management page

Related Products

Viral Respiratory Infection Array

Vivalytic Test Cartridges

Vivalytic

Vivalytic Test Menu


Request a meeting
×
Make an Enquiry - RX series
×
Make an Enquiry - Reagents
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Kit Insert Request - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
×
Make an Enquiry - Quality Control
×
Make an Enquiry - RIQAS
×
Make an Enquiry - RIQAS
×
Make an Enquiry - Quality Control
×
Make an Enquiry
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Biochip
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Molecular
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
  • This field is for validation purposes and should be left unchanged.
×
Make an Enquiry - Future Diagnostics
×
Make an Enquiry - RX series (Product)
×
Make an Enquiry - Quality Control
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - RIQAS
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Make an Enquiry - Reagents
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
Por favor, introduzca sus datos para ver nuestro Ćŗltimo seminario
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje Polityki Prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
  • Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności.
×
Wyślij zapytanie
    Rejestracja na naszej liście mailowej jest szybka i łatwa. Nie chcemy wysyłać e-maili zawierających spam lub wiadomości, ktĆ³re są automatycznie przekierowywane do kosza. W zawiązku z czym firma Randox deklaruje, że będzie wysyłac tylko informacje na temat nowych produktĆ³w,akutalizacji obecnych, trendĆ³w rynkowych, wydarzeń branżowych itp. Firma Randox Laboraotries obiecuje, że Państwa dane nie będą nigdzie przekazane, a przechowywanie owych danych będzie się odbywało z zachowaniem największego bezpieczeństwa. Prosimy o przeczytani naszje polityki prywatności .
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
    Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
ź·€ķ•˜ģ˜ ė¬øģ˜ ģ‚¬ķ•­ ģ œģ¶œ
×
Downloads
×
Contact

<p>

    Randox Clinical Chemistry Products Join the Randox Laboratories Mailing List * I would like to receive emails with new product releases and updates from Randox Laboratories, market trends, and more. I do not want to receive email marketing from Randox. Signing up to our mailing list is quick and easy. We do not want to send you any spam or junk emails, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promises never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
</p>

×
Enquire Now - Coronavirus Testing
  • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details safe and secure. Read more in our Privacy Policy.
×